Lv1
44 积分 2025-05-19 加入
Development of Dihydroquinoxalinone-Based Dual CDK6/BET Inhibitors for Triple-Negative Breast Cancer Therapy
25天前
已完结
Structure-Based Design of 4-(1-Methyl-1 H -indol-3-yl)pyrimidin-2-amine Derivatives as the First Covalent FGFR3 Selective Inhibitors
1个月前
已完结
Targeting the Androgen Receptor Pathway in Prostate Cancer: A PROTrACted Struggle
1个月前
已完结
DEVELOPMENT OF E3 LIGANDS TO ENABLE NEXT-GENERATION DEGRADERS
2个月前
已完结
Dual PARP/NAMPT Inhibitors for BRCA Wild-Type Triple-Negative Breast Cancer: Disrupting Homologous Recombination Repair and Activating Antitumor Immunity
2个月前
已完结
Development of PI3Kα inhibitors for tumor therapy
2个月前
已完结
Discovery and Characterization of PVTX-321 as a Potent and Orally Bioavailable Estrogen Receptor Degrader for ER+/HER2– Breast Cancer
2个月前
已完结
Branching beyond bifunctional linkers: synthesis of macrocyclic and trivalent PROTACs
2个月前
已完结
Approved Steroidal Drugs (2000–2025): A Medicinal Chemistry Perspective
2个月前
已完结
Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance
2个月前
已完结
皖公网安备34019202002308
